Mechanism of Sarcopenia in Heart Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorAarhus University Hospital
About this trial
The aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.
Eligibility criteria
Qualifiers
Ability to provide valid informed consent.
Heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
Disqualifiers
Cancer requiring treatment (e.g. prostate cancer on watchful waiting does not exclude patients).
Severe musculoskeletal or neurological disability.
Severe lung disease with a forced expiratory volume 1 < 40% of predicted. Treatment with anticoagulants (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) is an exclusion criterion for muscle biopsy. Patients with anticoagulant treatment will be invited to participate in the study without muscle biopsy.
Other comorbidities that prevent the patient from participating in the study examinations as judged by the investigator.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
250 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov